Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.

Grebely, J; Litwin, A; Dore, G J

Grebely, J; Litwin, A; Dore, G J.

Afiliação

Grebely J; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Litwin A; Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
Dore GJ; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.

J Viral Hepat ; 23(9): 664-6, 2016 09.

Article em En | MEDLINE | ID: mdl-27272285

Assuntos

Hepacivirus; Hepatite C; Antivirais; Humanos; Abuso de Substâncias por Via Intravenosa

Palavras-chave

IFN-free; PWID; drug users; hepatitis C virus; injecting; injection

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C / Hepacivirus Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google